Stay updated with breaking news from Pascal Nigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key patent now granted in major markets including the U.S., Europe, Canada & South KoreaPatent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit
Press release content from Accesswire. The AP news staff was not involved in its creation.
Press release content from Accesswire. The AP news staff was not involved in its creation.
RICHMOND HILL, ON / ACCESSWIRE / October 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment
Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results OVERVIEW The Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and nine-month periods ended April 30, 2021. For the three and nine-month periods ended April 30, 2020, net loss and total comprehensive loss totalled $2,489,000 and $6,896,000, respectively. The net loss and total comprehensive loss for the three-month period ending April 30, 2021, includes a net loss of $nil (2020 - $198,000) and for the nine-month period ending April 30, 2021 a gain of $1,536,000 (2020 - loss of $...